Alta Sciences

SEPTEMBER 27, 2024

The growing understanding of the immune system's role in various diseases, along with advancements in drug development, have led to a natural evolution from traditional vaccines, small molecules , and cytokines , to increased targeted biologics and innovative approaches in gene therapy and vaccines.

Clinical Trials 52

Clinical Trials Trials Pharmacokinetics Small Molecule 52

Drug Discovery World

FEBRUARY 13, 2024

The attention on this tool brought further waves of interest into how AI could be deployed across the pharmaceutical and drug discovery sectors. However, that’s not to say the future of drug discovery isn’t exciting, or that AI won’t play a part in it, just that the potential of AI within pharma has yet to be reached.

Small Molecule 147

Small Molecule Drugs Therapies Pharmaceutical Companies 147

Drug Discovery World

DECEMBER 26, 2023

Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical commented: “Otsuka is committed to the development of drugs for rare diseases such as autosomal dominant polycystic kidney disease (ADPKD).

Small Molecule 130

Small Molecule Drugs Molecular Biology Bioinformatics 130

LifeSciVC

AUGUST 5, 2024

We are constantly reminded how we are in the midst of an artificial intelligence revolution of the drug development process which promises to completely transform how we develop drugs with increases in productivity of an order of magnitude or more.

Molecular Biology 88

Molecular Biology Production Small Molecule Drug Development 88

Drug Discovery World

SEPTEMBER 9, 2024

Expanding accessible chemical space: Generative models have a remarkable ability to design novel drug-like molecules based on specific chemical or pharmacological properties, or even detailed molecular information about drug targets.

Drugs 162

Drugs Bioinformatics Computational Chemistry International 162

Sygnature Discovery

OCTOBER 10, 2023

Microglia are neuro-inflammatory cells that constitute ~10% of the brain’s cell population and are a key therapeutic target in the development of adequate treatments for Alzheimer’s Disease and other neurodegenerative conditions.

Small Molecule 52

Small Molecule Drugs Disease Clinical Trials 52

Broad Institute

AUGUST 13, 2024

Brain Health Scientific Community By Rose Circeo August 13, 2024 Breadcrumb Home Brain Health Brain Health Scientific Community PI Topic Paola Arlotta (Harvard) 3D cerebral organoid culture technologies to assess the molecular laws that govern the birth, differentiation, and assembly of the human cerebral cortex in health and disease.

Disease 52

Disease Small Molecule Engineering Government 52

The Pharma Data

MARCH 28, 2022

Dupixent peak sales ambition raised to more than €13 billion Chronic obstructive pulmonary disease 2023 pivotal readouts provide potential for additional Dupixent sales ambition upgrade 13 potential new medicines currently in the clinic to treat chronic inflammatory diseases, with 17 readouts expected by the end of 2024.

Small Molecule 52

Small Molecule Clinical Development Disease Science 52

Drug Discovery World

JANUARY 24, 2024

DDW’s Megan Thomas caught up with Wigerinck to learn more about his work with small molecules for fibrosis research. MT: Your appointment comes as Fibrocor seeks to advance two drug candidates – exquisitely specific kinase inhibitor small molecules (FIB992 and FIB991) for rare indications into the clinic.

Small Molecule 147

Small Molecule Research Pharma Companies Disease 147

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

Agency IQ

APRIL 19, 2024

BY LAURA DIANGELO, MPH | APR 15, 2024 10:06 PM CDT FDA’s Center for Drug Evaluation and Research (CDER) has a new initiative to advance clinical trials Quick background: The push for “innovation” in clinical trial design. So, adding new drug development tools is naturally, maybe not going to go over so well.”

Clinical Trials 40

Clinical Trials Trials Science FDA 40

Drug Discovery World

APRIL 30, 2024

Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. Whilst research into mRNA has been ongoing for decade, interest has sparked in recent years and research has begun to expand into areas of vaccinology, infectious diseases and other indications.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Conversations in Drug Development Trends

MAY 30, 2024

This trend is on the rise despite recent disappointments with clinical trial outcomes, which have the potential to destabilize the industry in the short term regarding drug development strategy and optimal study designs. The shared placebo design is another approach to accelerating drug development in ALS research.

Treatment 81

Treatment Small Molecule Clinical Trials Therapies 81

The Pharma Data

DECEMBER 14, 2020

It is considered an orphan disease for which there is no cure. billion by 2024, according to GlobalData, with the U.S. The ability of a drug candidate to cross the blood brain barrier is of critical importance in treatment outcomes for CNS and brain cancers. . representing the largest market.

DNA 52

DNA Clinical Trials Drugs Therapies 52

Drug Discovery World

JULY 24, 2024

Screening is an essential part of the drug discovery process in which researchers analyse large libraries of compounds in order to discover promising molecule that demonstrate a therapeutic effect against a disease target. This noteworthy ability opens the door for many targets that have been previously deemed intractable.”

Drugs 130

Drugs Small Molecule Disease Pharmaceuticals 130

Alta Sciences

JANUARY 31, 2024

Pharmacokinetics, Pharmacodynamics and Toxicokinetics Demystified pmjackson Wed, 01/31/2024 - 14:55 Understanding the effects of a drug, and how it interacts with the body, and vice versa, is critical to ensure it is safe for human use. As a drug travels through the bloodstream, it can form a strong bond with the drug-receptor site.

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Drug Development Small Molecule 52

Agency IQ

APRIL 19, 2024

FDA advisors endorse minimal residual disease (MRD) as accelerated approval endpoint for multiple myeloma Last week, FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously in favor of using minimal residual disease (MRD) as an accelerated approval endpoint for multiple myeloma.

FDA 40

FDA Disease Trials Clinical Trials 40

Elrig

APRIL 29, 2024

There, I supported AI-enabled DD efforts in their small molecule portfolio. Joining Isomorphic Labs in October 2024, I’m thrilled to be part of their mission to revolutionize DD through AI/ML. Fascinated by the potential of AI in medical research, I transitioned to BenevolentAI in early 2023 as a Biology Project Leader.

Bioinformatics 59

Bioinformatics Molecular Biology Drugs Cell Based Assays 59

New Drug Approvals

SEPTEMBER 13, 2024

4] [6] Aticaprant was originally developed by Eli Lilly , was under development by Cerecor for a time, and is now under development by Janssen Pharmaceuticals. [2] 12] Positron emission tomography imaging revealed that brain KORs were almost completely saturated by the drug 2.5 Drug Discovery. nM vs. 24.0

Treatment 62

Treatment Pharmacokinetics Clinical Trials Pharmaceuticals 62

Drug Target Review

FEBRUARY 15, 2024

Rising demand for animal protein has led to more factory farming, increasing the likelihood that diseases can spread among these animals then into humans. 5 Furthermore, ever larger numbers of humans are living in cities or travelling across borders, increasing the risk of diseases being transmitted person-to-person over a long range.

Drug Development 122

Drug Development Virus Vaccine Government 122

Agency IQ

FEBRUARY 23, 2024

Workshop addresses oncology dose optimization across full span of development In a series of broad-ranging, frank discussions, attendees at a joint FDA-American Association of Cancer Research (AACR) workshop worked through opportunities and challenges for dose optimization across the span of cancer drug development activities.

Science 40

Science FDA Trials Clinical Pharmacology 40

Agency IQ

DECEMBER 11, 2023

Diagnostic and therapeutic advances in oncology have moved many cancer types into the categories of curable or treatable diseases. In 2015, the FDA, along with the American Association for Cancer Research (AACR), held a workshop on dose optimization for small molecules.

FDA 40

FDA Science Clinical Trials Trials 40